- Investing Ideas
- /
- U.K. Pharmaceuticals & Biotech Potentially Undervalued Companies
U.K. Pharmaceuticals & Biotech Potentially Undervalued Companies
Results
204
0 new
Companies with a Value score of at least 3, ordered by Value score
204 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
0QCO | €0.73 | 1.5% | -34.9% | €495.5m | €1.79 | PS2x | E64.8% | n/a | ||
0O9B | €9.16 | 3.2% | -2.8% | €2.0b | €11.65 | PS2.1x | E50.7% | 2.0% | ||
0HF9 | US$10.57 | -2.2% | -4.8% | US$3.1b | US$17.20 | PS6.9x | E62.4% | n/a | ||
HIK | UK£19.04 | 0.4% | -8.2% | UK£4.2b | UK£22.86 | PE19.4x | E13.1% | 3.2% | ||
HVO | UK£0.28 | -2.1% | 37.4% | UK£188.8m | n/a | PE10.8x | E-15.2% | 0.7% | ||
0A5J | €33.50 | -4.1% | -13.7% | €1.8b | €50.43 | PE21.6x | E20.0% | 2.6% | ||
0W4N | €52.70 | -1.3% | 4.8% | €944.6m | €84.39 | PE14.8x | E30.7% | n/a | ||
0R1B | US$184.68 | -5.7% | -30.1% | US$27.0b | US$266.91 | PE23.3x | E17.1% | n/a | ||
0QAH | US$109.80 | -3.6% | 5.7% | US$278.2b | US$138.99 | PE20.3x | E14.4% | 2.8% | ||
HIKL | UK£19.06 | 0.6% | -7.9% | UK£4.2b | UK£22.89 | PE19.4x | E13.1% | 3.2% | ||
0Y5E | US$24.80 | -3.5% | -19.1% | US$3.4b | US$36.41 | PB0.7x | E59.3% | 4.4% | ||
INDVL | UK£7.84 | 5.4% | -52.3% | UK£1.0b | UK£17.82 | PS1.2x | E49.6% | 0% | ||
0LB2 | US$31.62 | 1.7% | 17.1% | US$1.8b | US$38.76 | PE336.8x | E61.3% | n/a | ||
INDV | UK£7.85 | 5.5% | -52.3% | UK£1.0b | UK£17.84 | PS1.2x | E49.6% | 0% | ||
0NTI | €78.70 | -19.4% | -21.7% | €2.7b | €113.88 | PE22.7x | E21.2% | 1.6% | ||
0LER | US$17.38 | -0.5% | 82.2% | US$19.8b | US$21.12 | PS1.2x | E56.8% | 0% | ||
C4XD | UK£0.12 | 45.9% | -16.4% | UK£30.3m | n/a | PE2.9x | E-88.3% | n/a | ||
0HL9 | US$3.18 | -7.6% | -32.4% | US$50.3m | US$30.86 | PS6.2x | E-10.6% | n/a | ||
0A5V | US$11.60 | 0.04% | 21.1% | US$13.8b | US$12.91 | PB0.7x | E14.4% | 4.1% | ||
0K16 | US$16.51 | 2.4% | 86.7% | US$1.0b | US$23.68 | PS4.3x | E71.4% | n/a | ||
COPNZ | CHF 75.50 | -0.3% | 100.3% | CHF 1.2b | CHF 97.06 | PE18.5x | E18.6% | 2.5% | ||
GSK | UK£14.60 | -5.0% | -2.7% | UK£59.5b | UK£19.54 | PE14.8x | E13.8% | 4.0% | ||
0K6R | US$113.61 | -1.9% | -0.8% | US$11.5b | US$168.02 | PE33.9x | E29.4% | n/a | ||
0H19 | SEK 14.18 | 2.7% | -13.5% | SEK 496.9m | SEK 21.17 | PB20.5x | E74.3% | n/a |